首页> European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)> Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system.

Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system.

导出原文传递

翻译打印收藏纠错

作者： Dalamaga M ^[1] ; Karmaniolas K ; Nikolaidou A ; Chamberland J ; Hsi A ; Dionyssiou-Asteriou A ; Mantzoros CS

作者单位： Department of Clinical Biochemistry, Medical School, University of Athens, Attikon General University Hospital, Chaidari, Athens, Greece. ^[1]

关键词 Adiponectin Aged 80 and over Body Mass Index Case-Control Studies 老年人 80以上人体质量指数病例对照研究胰岛素样生长因子Ⅰ 骨髓增生异常综合征

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

European journal of cancer

2008年44卷12期

1744-1753页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

European journal of cancer

2008年44卷12期

1744-1753页

检索历史清除

Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system.

European journal of cancer

相似文献

European journal of cancer

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system.

European journal of cancer

相似文献

European journal of cancer

相关期刊

检索历史清除